Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Lars W. P. van der Laan"'
Autor:
Michele P. Andrasik, Weiping Deng, Yiwen Lu, Bob C. Lin, Ruben O. Donis, Youyi Fong, Mira Baron, Lindsay N. Carpp, Lars W. P. van der Laan, Immune Assays Team, Adrian B. McDermott, Karen Martins, Lindsey R. Baden, Flora Castellino, James G. Kublin, Luis De La Cruz, Honghong Zhou, Chuong Huynh, Rolando Pajon, Amanda Eaton, David Benkeser, Mark Kutner, Dean Follmann, Marcella Sarzotti-Kelsoe, CoVPN Biostatistics Team, Hana M. El Sahly, Charlene McDanal, Jacqueline Miller, Christopher R. Houchens, Nima S. Hejazi, Kathleen M. Neuzil, Spyros A. Kalams, Bhavesh Borate, Coronavirus Efficacy (Cove) Team, David C. Montefiori, Lakshmi Jayashankar, Colleen F. Kelley, Richard A. Koup, Britta Flach, Peter B. Gilbert, Lawrence Corey, Chenchen Yu
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 4
article-version (status) pre
article-version (number) 4
BackgroundIn the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ffccfeae7ead57a33edd54278a0c324
https://doi.org/10.1101/2021.08.09.21261290
https://doi.org/10.1101/2021.08.09.21261290